Sanofi Pharma Day 2021

October 18, 2021 8:00 AM - 6:00 PM

MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139

Add to Calendar 10/18/2021 8:00:00 AM 10/18/2021 6:00:00 PM Sanofi Pharma Day 2021

Accelerate your emerging company or idea at Sanofi’s 2021 Pharma Days on October 18 & 19.  
 

MassBio’s Pharma Days are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. 

Please note that in-person attendees are required to be fully vaccinated to participate in the event. Additionally, masks will be required in all common areas of the event space except for when eating or drinking; in meeting rooms, attendees can remove masks if they feel comfortable doing so.
 

Engage on October 18 from 8 - 9AM ET | Hear from Sanofi leadership during a fireside chat about how Sanofi is evolving to meet the needs of an ever-changing innovation landscape. This livestreamed session will feature: 

  • John Reed, Executive Vice President, Global Head of Research and Development, Sanofi
  • Alban de La Sablière, Head of Partnering, Sanofi
  • Frank Nestle, Global Head of Research, Sanofi


Discover on October 18 from 3 - 4PM ET | Join Sanofi’s information session for the latest insights on its R&D strategy and therapeutic focus areas in immunology and inflammation (I&I) and cell and gene therapies. This hybrid session will feature:

  • John Bertin, Global Head of the Immunology and Inflammation Research Therapeutic Area, Sanofi
  • Christian Mueller, Global Head of Genomic Medicine Unit, Sanofi


Connect on October 18 & 19 | Meet one-on-one with Sanofi representatives to discuss collaboration opportunities. Sanofi’s specific areas of interest are: 

  • Cell and gene therapies, including gene editing and non-viral delivery technologies 
  • Immunology and inflammation, with a focus on dermatology, respiratory, and gastro-intestinal indications   


Eligibility Guidelines
Sanofi is open to connecting with groundbreaking innovators across all stages of development that have a strong understanding of their technology’s path to product. Sanofi is particularly interested in tangible assets or disruptive technologies.

Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with Sanofi representatives. Please note that these representatives did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed. 

 MassBioHub & Virtual, 700 Technology Sq Fl 5 Cambridge MA 02139
  • John Bertin
  • Global Head of the Immunology and Inflammation Research Therapeutic Area, Sanofi
  • John Bertin is the Global Head of the Immunology and Inflammation Research Therapeutic Area at Sanofi. He joined Sanofi in 2020 from GlaxoSmithKline where he was Vice-President and Head of Discovery and Early Development for Innate Immunology. John joined GSK in 2008 from Synta Pharmaceuticals where he was Senior Director of Translational Biology. Previously, he was a Senior Scientist in Immuno-Inflammation at Millennium Pharmaceuticals. John is best known for his pioneering work in the fields of cell death and inflammation, including the advancement of the first RIPK1 inhibitor into clinical studies, and contributions towards the discovery of the nodosome and inflammasome signaling complexes. He has co-authored more than 125 scientific articles and has been issued 25 patents on immune targets. John completed his postdoctoral studies at the National Institute of Allergy and Infectious Diseases, National Institutes of Health and at the Institute for Molecular Virology at the University of Wisconsin-Madison. He received his Ph.D. in Microbiology and Immunology from McGill University in Montreal, Canada.
  • See All Sessions
  • Alban de-la-Sabliere
  • Head of Partnering, Sanofi
  • Alban de La Sablière was appointed in November 2019 SVP Global Head of Sanofi Partnering, that includes Sanofi Ventures Fund, Business Development & Licensing and Alliance Management. He was previously SVP Head of Business Development & Licensing since October 2018 . Over the last two years, Alban oversaw a repositioning of the Business Development activities in line with Sanofi strategy, including significant partnership deals with, among others, Denali, BioNtech, Kiadis, Kymera, Mab Discovery, Translate Bio and ventures investments into Escient, NodThera, Lava Therapeutics. Alban joined Sanofi in January 2016 as SVP, Head of Mergers & Acquisitions. In this role he led the Bioverativ, Ablynx and Protein Sciences acquisitions and numerous portfolio reshaping disposals, including the sales of Zentiva. Prior to joining Sanofi, Alban worked for Morgan Stanley, where he worked with Sanofi on a number of important deals, including the merger of Sanofi & Aventis and the acquisition of Sanofi Genzyme.
  • See All Sessions
  • Christian Mueller
  • Global Head of Genomic Medicine Unit, Sanofi
  • Christian Mueller, Ph.D., is the Global Head of the Genomic Medicine Unit at Sanofi focusing on delivering transformative treatments for both rare and common diseases using viral, non-viral and cell therapies. As a former tenured faculty at the University of Massachusetts Medical Center, Dr. Mueller had a distinguished academic research career becoming an established thought leader in gene therapy, developing novel vector platforms, gene and base editing approaches, and mechanisms of gene silencing in the liver and CNS. Dr. Mueller has worked on translating AAV mediated gene therapies to the clinic for AATD, Huntington’s Disease and ALS. Notably he was the first to describe regulatory T- cell responses to the AAV capsid in patients, as well as the first to translate AAV mediated RNAi into the clinic in SOD1 ALS patients. He has been the recipient of many honors and awards for his research, including the Bettina Irvine Family Award for Excellence in Alpha-1 Research, and the ALS Angel Fund Angel Award.  In 2017, he was honored for holding one of the top 12 patents in Massachusetts by the Boston Patent Law Association, for inventing dual function AAV vectors with a silence and replace modality, among many other recognitions of his work. He is also the scientific founder and board member of Apic Bio and scientific founder of Tuned Therapeutics. Dr. Mueller received his Ph.D. in genetics from the University of Florida and M.Sc. in clinical investigation from the University of Massachusetts as Parker B. Francis Fellow.
  • See All Sessions
  • Frank Nestle
  • Global Head of Research, Sanofi
  • Frank O. Nestle, M.D. FMedSci is currently Global Head of Research and Chief Scientific Officer at Sanofi with responsibility for Sanofi’s main therapeutic areas of Immunology & Inflammation, Oncology including Immuno-Oncology, Neurology, Rare Diseases, Hematology and Genomic Medicine with a mandate to innovate and accelerate first and best in class medicines from discovery to clinical translation. Frank joined Sanofi in 2016 as founding Therapeutic Area Head for Immunology & Inflammation Research where he established the current organizational structure, recruited a cadre of leading immune-scientists and built a portfolio of first and best in class clinical candidate molecules with 15 immunology new molecular entities currently in clinical Development. Before joining Sanofi, Frank was a Professor and Chair of Cutaneous Medicine at King’s College London (United Kingdom) and practiced medicine at Guy’s and St. Thomas’ Hospital, the leading UK University Hospital, where he was also a member of the Board of Directors. At King’s College, Frank led research, translational clinical trials, and teams in Dermatology, Allergology and Immunology. In addition, he held several executive roles, in particular at the Guy’s and St Thomas’ Biomedical Research Center. He built the Clinical Research Facilities and led the Biomarker and Co-Diagnostics Cluster overseeing cross-disease area precision medicine projects and translational research platforms including Genomics, Flow Cytometry, Translational Bioinformatics and Bioresource. Frank is a Fellow of the Academy of Medical Sciences, a Senior Investigator Emeritus at the National Institute for Health Research (NIHR) and Past-President of the Federation of Clinical Immunology Societies (FOCIS).
  • See All Sessions
  • John Reed
  • Executive Vice President, Global Head of Research and Development, Sanofi
  • Dr. Reed, Executive Vice President, serves as the global head of Pharmaceutical Research & Development for Sanofi, reporting to the CEO and participating as a member of the company’s Executive Committee. Prior to joining Sanofi in May 2018, Dr. Reed served as global head of pharmaceutical research and early development at Roche (Basel, Switzerland) for five years (2013-2018). From 2002 to 2013, Dr. Reed served as CEO of Sanford-Burnham Medical Research Institute, La Jolla, California and ran a highly productive laboratory that generated more than 900 research publications, over 130 patents, and that was awarded more than one-hundred research grants and trained over 100 post-doctoral fellows. Dr. Reed served on multiple editorial boards of research journals. He was scientific founder or co-founder of four biotechnology companies. Dr. Reed also served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations. During his academic career, Dr. Reed held faculty appointments at several universities. He is a Fellow of the American Association for the Advancement of Science (AAAS) and a recipient of numerous honors and awards for his accomplishments in biomedical research. Dr. Reed obtained his M.D. (medicine) and Ph.D. (immunology) degrees from University of Pennsylvania in 1986 (graduating Alpha Omega Alpha) and his B.A. degree (chemistry) from University of Virginia in 1980 (graduating Phi Kappa Phi). His post-graduate training included residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania and a post-doctoral fellowship in Molecular Biology at Wistar Institute (Philadelphia).
  • See All Sessions

Brought to you by